VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 83 filers reported holding VAXCYTE INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,545,000 | +27.3% | 30,306 | +24.7% | 0.00% | – |
| Q2 2023 | $1,213,542 | -96.3% | 24,300 | -97.2% | 0.00% | -100.0% |
| Q1 2023 | $32,398,087 | -33.6% | 864,410 | -15.1% | 0.01% | -41.7% |
| Q4 2022 | $48,820,676 | +31.6% | 1,018,158 | -34.1% | 0.01% | +33.3% |
| Q3 2022 | $37,094,000 | +43.6% | 1,545,567 | +30.2% | 0.01% | +28.6% |
| Q2 2022 | $25,829,000 | +46.6% | 1,186,986 | +62.7% | 0.01% | +75.0% |
| Q1 2022 | $17,619,000 | +679.3% | 729,555 | +667.5% | 0.00% | – |
| Q4 2021 | $2,261,000 | +51.6% | 95,050 | +61.8% | 0.00% | – |
| Q3 2021 | $1,491,000 | -37.1% | 58,734 | -44.2% | 0.00% | – |
| Q2 2021 | $2,370,000 | +8.3% | 105,297 | -5.0% | 0.00% | -100.0% |
| Q1 2021 | $2,189,000 | -57.7% | 110,837 | -43.1% | 0.00% | 0.0% |
| Q4 2020 | $5,176,000 | +99.5% | 194,811 | +270.7% | 0.00% | 0.0% |
| Q3 2020 | $2,595,000 | -85.1% | 52,559 | -90.4% | 0.00% | -83.3% |
| Q2 2020 | $17,377,000 | – | 549,751 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $99,174,000 | 24.03% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $44,903,000 | 11.24% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,111,485 | $26,442,000 | 11.06% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $54,944,000 | 4.23% |
| Kynam Capital Management, LP | 211,483 | $5,031,000 | 2.69% |
| GREAT POINT PARTNERS LLC | 500,000 | $11,895,000 | 2.64% |
| Ghost Tree Capital, LLC | 250,000 | $5,948,000 | 2.13% |
| RA Capital Management | 4,240,464 | $100,881,000 | 1.78% |
| Opaleye Management Inc. | 315,800 | $7,513,000 | 1.59% |
| Ikarian Capital, LLC | 295,111 | $7,021,000 | 1.05% |